arrow
A

Alice Bernard-Tessier

department of cancer medicine, gustave roussy, villejuif, france, paris-saclay university, kremlin-bicetre, france
H指数:16
被引数:1,017

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: results from the first-in-human STESIDES study

ODM-209类固醇生成抑制剂用于转移性去势抵抗性前列腺癌和晚期乳腺癌:来自首次人体STESIDES研究的结果

2026-09-120
PRE
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair–deficient Metastatic Castration-resistant Prostate Cancer

PD-(L)1免疫疗法在DNA错配修复缺陷型转移性去势抵抗性前列腺癌患者中的疗效

2025-07-120
OAAI
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

评估接受或不接受阿比特龙醋酸盐联合泼尼松治疗的初始转移性去势敏感前列腺癌男性患者的骨矿物质密度:PEACE-1 III期试验

2025-03-011
PRE
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration- resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

先前接受卡巴他赛治疗的转移性去势抵抗性前列腺癌患者的177前列腺特异性膜抗原活性和预后决定因素: PACAP研究

2024-10-010
OA
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer

去势抵抗性前列腺癌侵袭性变异体新模型的建立

2024-06-011
PRE
Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal single-cell analysis of patient tumors identifies biological correlates of response to PARP inhibitors and anti-PD-L1 therapy
2024-03-220
PRE
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
2024-02-015
PRE
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study
2023-11-011
PRE
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
2023-04-0132
OAAI
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging
RADIOLOGY
IF15.2
2023-01-0124
PRE
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

Folfox-bevacizumab治疗结直肠癌失败后的FOLFIRI联合贝伐单抗或阿柏西普 (BEFLICO): 一项AGEO多中心研究

2022-07-147
OA
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer
DRUGS
IF14.4
2022-05-0513
PRE